Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increase in the prevalence of chronic pain
3.2.1.2 Increase in incident of trauma and surgeries
3.2.1.3 Rise in geriatric population
3.2.1.4 Advancement in drug delivery system
3.2.2 Industry pitfalls & challenges
3.2.2.1 Regulatory restrictions
3.2.2.2 Alternative pain management technologies
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter’s analysis
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Short-acting oxycodone
5.3 Long-acting oxycodone
Chapter 6 Market Estimates and Forecast, By Dosage Form, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Tablets
6.3 Capsules
6.4 Injections
Chapter 7 Market Estimates and Forecast, By Indication, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Neuropathic pain
7.3 Musculoskeletal pain
7.4 Cancer pain
7.5 Post-operative pain
7.6 Other indications
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Drug stores & retail pharmacies
8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Alvogen
10.2 Ani Pharmaceutical Inc.
10.3 Daiichi Sankyo Company Ltd.
10.4 Endo Pharmaceuticals
10.5 Mallinckrodt Pharmaceuticals
10.6 Mylan N.V.
10.7 Protega Pharmaceuticals LLC
10.8 Purdue Pharma LP
10.9 Quagen Pharma
10.10 Teva Pharmaceuticals, Inc.
